Siana Capital: Deep Science Meets Patient Capital — the Fund Built for Hard Tech Founders

Building hard technology takes longer than software — longer product cycles, longer sales cycles, a longer road to scale. Most VCs are allergic to that timeline. Siana Capital is built for it: a venture fund manager "specializing in the deep tech and science domains of the India growth story", with a 10-year fund horizon designed around the reality of deep-innovation startups. Typical cheques: $1–3 million, written at the inflection point where a company has stabilised product-market fit and is about to scale explosively.

Investment thesis

Siana invests in "deep innovation" — ideas driven by science and technology that are path-breaking with high profitability potential, and possibly socially relevant. The risk equation is managed through technology and IP differentiation, competitive advantage and market defensibility. Unusually, the fund targets companies that already have stabilised product-market fit but are at the inflection point of explosive market growth — avoiding pure seed-stage risk while still playing the early value-creation game, and staying closely engaged with investee firms through to a profitable exit.

Sectors & stages

Sectors span Artificial Intelligence, AgriTech, Biotech, BioSciences, CleanTech, FinTech, Healthcare, SaaS and Virtual Reality — deep-science domains where the firm holds genuine technical literacy. Stages are primarily Series A and Series B, deliberately entering before exit to capture early value creation without seed-stage risk. The first fund was designed for around 15 portfolio companies.

Fund size & cheque sizes

Siana's vehicle is the Deep Science India Fund Trust (a SEBI-registered venture fund). When it launched, the firm targeted a first close of ₹500 crore for its debut fund. Typical investment tickets are $1 million to $3 million (₹10–35 crore range). The final corpus is not publicly disclosed.

Notable portfolio

Portfolio companies include ekincare (health benefits platform), Proklean (green chemistry), Ayekart (agri-fintech), Zumutor Biologics and Produktiv — plus an exit in agritech marketplace Gramophone, one of the fund's most notable early outcomes.

Partners & team

Founded in late 2017 by Dr. Siddharth (Sid) Pai and Dr. Archana Hingorani, with Dinesh Goel as Partner. Pai, Co-founder & Managing Partner, is a former Chief Strategy Officer at ISG with over 35 years of finance and technology consulting experience and a doctorate in technology from Purdue University. Hingorani, also Co-founder & Managing Partner, was CEO & ED of IL&FS Investment Managers and a founding member of IL&FS Private Equity — with over $3.8 billion managed across 150 transactions, plus a doctorate in finance from the University of Pittsburgh. Goel spent over a decade as ISG's Partner and India Managing Director. Principals Varun Kapoor (CFA) and Siddharth Shah (FRM) round out a team with 100+ years of cumulative experience across technology, operations and investments.

Programmes run

Siana does not operate an accelerator. Its differentiation is engagement depth: the team has worked jointly on transactions since 2018 and stays closely involved with portfolio companies on strategic decisions, go-to-market and global network access, supported by advisory boards with environment, governance, social, scientific and technology expertise.

Credits & perks

No founder credits or perks programme is publicly disclosed.

How to engage

Founders with science-led ventures that have reached stabilised product-market fit can engage through the firm's website (sianacapital.com). Given the partners' consulting and large-contract backgrounds, technical differentiation and a defensible IP position should lead the pitch — the firm explicitly wants to see what makes your technology defensible.